Merck shares fall as 2026 guidance disappoints despite solid Q4 results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Merck (MRK) PT Raised to $132 at BofA Securities
February 4, 2026 5:48 AM ESTBofA Securities analyst Tim Anderson raised the price target on Merck (NYSE: MRK) to $132.00 (from $124.00) while maintaining a Buy rating.
The analyst comments "Post 4Q, we reduce our MRK 2026 sales and EPS to reflect greater conservatism around some LOE products, US... More
